Senseonics Holdings, Inc. (SENS) NASDAQ
5.71
+0.17(+3.07%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.71
+0.17(+3.07%)
Currency In USD
| Previous Close | 5.54 |
| Open | 5.55 |
| Day High | 5.75 |
| Day Low | 5.48 |
| 52-Week High | 12.58 |
| 52-Week Low | 4.79 |
| Volume | 358,678 |
| Average Volume | 724,542 |
| Market Cap | 238.64M |
| PE | -2.9 |
| EPS | -1.97 |
| Moving Average 50 Days | 6.29 |
| Moving Average 200 Days | 7.33 |
| Change | 0.17 |
Sequel Med Tech and Senseonics Launch Transformative Combination of twiist™ and Eversense® 365
GlobeNewswire Inc.
Feb 19, 2026 1:00 PM GMT
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetesMANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transforma
Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
GlobeNewswire Inc.
Jan 29, 2026 9:01 PM GMT
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people w
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
GlobeNewswire Inc.
Jan 28, 2026 9:05 PM GMT
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people